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systematic and random error for individual and population were 
calculated. 
Results: The data showed that the system was able to correct shifts 
with an accuracy of 3 mm. The population systematic errors were 0.7 
mm in L – R direction, 0.6 mm in S – I direction for anterior field and 
0.9 mm in A-P direction 0.5mm in S – I direction for lateral field. The 
population random errors were 1.4 mm in L – R direction, 1.1 mm in S 
– I direction for anterior field and 0.9 mm in A -P direction 1.0 mm in 
S – I direction for lateral field.The displacement more than 3 mm 
(negative orpositive) was 4.17 % in S-I direction, 5.88 % in L-R 
direction, 6.41% in A-P direction. 
Conclusions: The current set up for irradiation head & neck cancer 
patients using IMRT in our department is accurate. The mean set-up 
error is less than 3 mm . EPIs can promptly detect interfactional set – 
up errors in patients during radiotherapy and help radiation therapist 
to improve set up accuracy. It is a useful device for radiation therapy 
quality assurance (QA) and quality control (QC).  
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Purpose/Objective: In recent years new radiation therapy (RT) 
techniques have emerged, that have changed the way treatments are 
done in the RT service, emphasizing the importance of accuracy in all 
the stages of treatment.Whatever, the technique of RT positioning of 
the patient is crucial for the successful treatment, as their 
verification frequency, along the various fractions, established with 
suitable protocols. As a control tool for positioning the patient, the 
various techniques of Image Guided Radiation Therapy (IGRT) allow us 
to assess the position, and the location of the target volume and 
organs at risk (OARs) before treatment.The aim of this study was the 
validation of CTV – PTV margins, in prostate cancer patients. The dose 
distribution was compared in GTV and CTV volumes, calculated in 
CBCT images, acquired for treatment verification, with CT planning 
images. The dose calculation was also validated on CBCT images. 
Materials and Methods: Images from Computed Tomography (CT) 
scans were acquired out of 19 patients with prostate carcinoma, 
delineated target volumes and OARs, and carried out the plan in 
dosimetric planning system (TPS).Subsequently, the CBCTs were 
acquired in the treatment machine and performed co-registration 
with CT planning before treatment. In the TPS we reproduced the 
conditions of the treatment in the CBCTs, with and without the 
corrections madein the daily treatment (on-line), and calculated the 
dosimetric plans of the CTin the 166 CBCTs acquired, for comparison 
of the V95% D98 %and D100%. 
Results: The obtained V95% of CBCTs with correction was 100% in 
almost all patients, except one who was 98.8%. In CBCTs with 
corrections the D98% and D100% were above 95% for all patients. 
Conclusions: The coverage of the target volume with the prescribed 
dose has been achieved in all patients and it was possible to 
reproduce the dosimetric plan of the CT in CBCTs. 
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Purpose/Objective: PET–CT scans are commonly used for the purpose 
of gross tumour volume (GTV) delineation in head and neck cancers. 
Qualitative visual methods (QVM) are currently employed in most 
radiotherapy departments but these are subject to inter- and intra- 
observer variability. The aim of this evaluation was to assess the 
reliability of quantitative thresholding methods to aid GTV 
delineation. 
Materials and Methods: Quantitative thresholding methods which 
appear in the published literature are evaluated with respect to their 
reliability for delineation of GTVs in head and neck cancers. 
Results: Image segmentation involves the application of a distinct 
value to all pixels or voxels in an image dataset. This is a complex 
process affected by numerous variables. Some of the following 
segmentation thresholds may be applied to automatically delineate 
specified regions. Standardised uptake value (SUV) is commonly used 
to apply a threshold for GTV delineation, however this leads to 
inappropriately large GTVs in head and neck tumours. A further 
common quantitative threshold is based on the maximum signal on the 
PET image relative to the background uptake, known as signal to 
background ratio (SBR). This method generates GTVs that correlate 
well with surgically removed tumour volumes. Applying a fixed 
threshold of a percentage of the maximal intensity uptake is also 
documented in the literature but was found to be unsuitable for the 
purpose of head and neck GTV contouring. Systems generating 
volumes based on the physical features of the PET-CT images are also 
discussed and are found to produce very promising results. 
Conclusions: A number of quantitative techniques are evaluated and 
currently the most suitable is found to be SBR, however even this 
method was not found to be entirely reliable. 
More promising techniques need further evaluation before they could 
be implemented clinically and a Radiation Oncologist or Nuclear 
Medicine Radiologist must still validate all GTVs produced by 
quantitative methods. 
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Purpose/Objective: In our institution the tumour bed is localised via 
the implantation of surgical titanium clips at the point of surgery [1] 
and verified on the treatment unit with kV imaging and a daily online 
‘shift to zero’ policy. As this is a relatively new process within the 
department, and in the light of the recent national IGRT guidance 
document [2], we have decided to audit an initial cohort of patients 
for adherence to, and robustness of, our departmental imaging 
protocol.  
References available on request. 
Materials and Methods: A retrospective review was carried out to 
assess the set-up variation of an initial cohort of patients. Daily kV 
online match values based on ‘Centre of Mass’ of the clips were 
extracted from the ARIA database (Varian Medical Systems). The data 
was analysed for the entire cohort and separately for those patients 
that had had a simultaneous integrated boost or sequential boost in 
the light of a 7mm departmental imaging tolerance. 
Results: The first thirty breast patients who had completed their 
course of radiotherapy teir ath were included in the review with a 
total of 415 image matches. 21 patients had a simultaneous integrated 
boost (daily kV imaging) and the remaining nine patients a sequential 
boost (daily kV imaging on boost only).  
The mean shifts applied for the entire cohort were: 
VRT: 0.29cm (SD ± 0.22; Range 0-1.0 cm); LNG: 0.25cm (SD ± 0.20; 
Range 0-0.9cm); LAT: 0.24cm (SD ± 0.30; Range 0-0.7cm) 
The systematic difference between CT and treatment for this cohort 
was: 
VRT: -0.14cm (SD ±0.33); LNG: 0.03cm (SD ±0.32); LAT: -0.06cm (SD 
±0.29) 
This suggests that there maybe a systematic difference in the ‘centre 
of mass’ in the vertical direction, possibly due to the patients relaxing 
during treatment compared with CT or posterior movement of the 
clips. There was no difference in match data between the 
simultaneous integrated boost cohort and the sequential boost cohort. 
Conclusions: This audit shows that the 7mm imaging protocol used by 
our institution for the clip matching of breast patients is adequate. 
Further work needs to be carried out to evaluate whether a non–daily 
protocol would be sufficient for target verification hence reducing 
imaging dose. The variation in set-up is multi-factorial and includes, 
patient position, respiratory motion, tumour bed volume changes and 
clip position changes. This data, however, cannot describe the 
individual contribution from these factors. Inclusion of more patients 
into the audit may assist in the development of a non-daily protocol 
and examining individual clip position may provide information on 
tumour bed motion and volume changes.  
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Purpose/Objective: The purpose of this study was to verify safety 
interlocks consistent with international standards IEC 60601-2-1 using 
a linear accelerator Coline 6 control system developed through the 
European Accelerators & Detectors AiD Project (AiD project: 
Development of dedicated systems based on accelerators and 
detectors of ionizing radiation for medical therapy and indetection of 
hazardous materials and toxic wastes) in The Polish National Centre 
for Nuclear Research. 
Materials and Methods: The pre-prototype of the control system 
works with the registration and verification software developed in the 
National Centre for Nuclear Research and Treatment Planning System 
PHJ Prague.The system analysis was performed to assess the security 
operation responsible for the dose off including verifications of error 
messages of measurement doses related to dosimetry measurement 
devices, mechanical failure of accelerator elements and use by an 
unauthorized user. Before starting the irradiations various cases 
ofoperator errors, omissions in remote data retrieval therapy and 
manual dialing parameters were tested. During the irradiations 
different schedules of dose measurements device and accelerator 
mechanical device errors were tested. 
Results: Safety of the patient during the irradiation is dependent on 
the manufacturer of the treatment devices. The accelerator control 
system was designed to meet all treatment parameters obtained from 
the Treatment Planning System and terminated irradiation if the 
parameters were inconsistent with the plan. The pre-prototype of the 
control system met all requirements. 
Conclusions: The analysis of the cases used in this study showed that 
the control system created as a pre-prototype can be the first step to 
create clinically acceptable software. 
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Purpose/Objective: The importance in local control and toxicity of 
optimal applicator placement in cervical cancer brachytherapy (BT) is 
well established. Nevertheless uterine perforation remains a frequent 
complication, generally undetected by classic QA measures of 2D BT 
to assess the adequacy of implant placement. 3D BT based on CT 
imaging allows optimal visualization of applicator’s position in respect 
to the OARs thus enabling the possibility of dose optimization. Aim of 
this work is to define the dosimetric impact on OARs of undetected 
uterine perforation when a standard point A optimized dose 
distribution is applied and the eventual dosimetric gain achievable 
with 3D CT-based dose optimization. 
Materials and Methods: 23 CT-based tandem/ovoids BT applications 
complicated by uterine perforation were selected. All patients had a 
FIGO IIB cervical cancer and were planned to receive radio-
chemotherapy (1.8 Gy per fraction up to 45 Gy with concomitant 
weekly cisplatin) and BT (4 fractions of 7 Gy) with a plan optimized to 
HRCTV drawn according clinical findings at the time of BT. The 
planning aim for dose optimization was to keep the D2cc value for 
rectum, bladder and sigmoid below 4.6 Gy, 6.5 Gy and 4.6 Gy 
respectively. Moreover a standard point A plan was calculated and 
respective DVH parameters for HRCTVs and OARs compared. Wilcoxon 
test was applied for statistical data analysis and calculated with 
Matlab 7.11 software (Mathworks Inc). 
Results: Median HRCTV width was 46 mm (37-64 range). Median 
HRCTV D90 and OAR D2cc values achieved with standard or the 
optimized plan are listed in table 1. When the standard plan was 
applied the intended dosimetric constraint for rectum, bladder and 
sigmoid were not achieved in 15 (60%), 10 (43,5%) and 19 (82%) 
applications respectively while they were always met in the 3D 
optimized plans. In 8 out of the 19 standard plans where the 
dosimetric constraint was exceeded the sigmoid D2cc was higher than 
8Gy. In 3 cases out of 19 it was higher than10Gy. 
 
*p-value < 0,001 Standard plan Optimized plan 
HRCTV D90 (Gy) * 7,5 (range 6 – 10,1) 6,4 (range 4,8 – 9,6) 
Rectum D2cc (Gy) * 5,2 (range 2,33 - 6,73) 4,5 (range 2,68 – 4,71) 
Bladder D2cc (Gy) 6,3 (range 3,8 - 17,6) 6,1 (range 4,34 – 6,4) 
Sigmoid D2cc (Gy)* 6,8 (range 1,78 – 16,75) 2,9 (range 0,8 – 4,65) 
 
Conclusions: The occurrence of uterine perforation should be kept as 
low as possible by the routine use of US during GYN BT implantation. 
When uterine perforation occurs it is easily detected on CT images but 
rarely on the orthogonal films. In case of uterine perforation 2D 
planning may thus results in potentially dangerous over dosage of 
OARs. 3D optimization allows keeping OAR dose within tolerance 
constraints just minimally compromising HRCTV D90 coverage.  
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Purpose/Objective: To evaluate if glycosaminoglycan’s (GAG) 
administration as hyaluronicacid (HA) intravesical instillations reduces 
the rate of acute and lateradio induced bladder toxicity as a 
complication of radiation treatment in gynecological cancer. A review 
of the literature was done to analyse which treatments were used in 
this field and the HA role among them. 
Materials and Methods: Retrospective study of 70 patients diagnosed 
with cervical and endometrial cancer treated between May 2010 and 
June 2012 with high-dose rate brachytherapy (HDR-BT) with or 
without external beam radiotherapy (EBRT). 50/70 received an EBRT 
total dose of 45-50.4 Gy delivered in 25-28 fractions followed by 
brachytherapy (HDR-BT) 11Gy in 2 fractions. The remaining 20 
patients received HDR-BT alone, 21 Gy in 3 fractions. All of them 
received intravesical instillations of hyaluronic acid (HA) immediately 
after each HDR-BT fraction according to recommendations of medical 
prospectus. 5/50 (10%) presented G1-2 toxicity before brachytherapy. 
RTOG/EORTC scale was used to evaluate acute and late toxicity rates 
at 3, 6, 12 and 18 months after HDR-BT. A review of the literature was 
made using Medline research with the following criteria: HA 
prevention and gynecological cancer and radioinduced cystitis. 
Results: Regarding our study, no upgrading toxicity was observed in 
patients treated with combined HDR-BT and EBRT (50/70) during the 
follow-up period. None of the patients (20/70) treated with exclusive 
HDR-BT had bladder toxicity neither acute nor chronic. No adverse 
events related to HA were observed. After reviewing literature, we 
observed that HA instillations have demonstrated effectiveness in 
relieving symptoms associated with interstitial cystitis, considering a 
similar biological pattern to radioinduced cystitis. 2 studies with these 
characteristics and written by the same authors were found: P. 
Samper et al. The first one is an abstract presented at ASCO 2003 with 
90 patients and the other a retrospective study with 95 patients; both 
of them demonstrate that HA instillations are effective in 
radioinduced cystitis prevention.  
Conclusions: Intravesical instillations of hyaluronic acid are effective 
in preventing radiation cystitis. It is safe and well tolerated. Given the 
scarcity reports on this subject, it is difficult to draw any firm 
conclusions about standard recommendations. However, based on our 
experience, intravesical HA can be used as routine before each 
brachytherapy fraction in gynecological cancer. A prospective 
randomized control study with a large number of patients and long 
term follow-up is recommended. 
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Vaginal brachytherapy for endometrial cancer: pulsed dose rate 
versus low dose rate, a single institution analysis. 
